America and Britain Conclude Duty-Free Accord on Prescription Drugs.

The UK and US have announced a significant commercial pact that will keep zero duties on British pharmaceutical shipments entering the US market.

The Terms of the Pact

Under the terms of the agreement, the UK has agreed to boost funding on medicines through the NHS. This commitment secures that tariffs on these vital exports will stay at nothing for a period of three years.

This development is in response to recent warnings to dramatically increase tariffs on patented drug products, with increases discussed as high as 100%.

"This arrangement between the Britain reinforces the worldwide climate for new treatments and establishes long-overdue balance to American-British medicine commerce," an announcement declared.

Economic Importance

Pharmaceuticals constitute one of the the United Kingdom's largest exports to the America, which is by far the biggest market for large companies like GSK and AstraZeneca.

Trade data show that in the one-year period to the end of last September, the UK shipped pharmaceutical products totaling billions to the US. This value accounted for 17.4% of total UK exports in that span.

"This guarantee protects work, increases funding and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.

Specific UK Commitments

The agreement includes several notable pledges from the UK:

• Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be prohibitively costly by twenty-five percent.
• Increased NHS Spending: There is a aim to raise total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
• Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, rebates were more than 20%.

Recent Tensions

The pact follows a protracted tension between the drug companies and the ministers over drug pricing and approval rates.

These tensions were heightened by assertions that US patients were charged significantly more for the equivalent treatments than people in the other developed nations.

Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while substantial investments have been pledged toward American operations.

A senior figure publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.